Alvogen launches Inflectra into Central and Eastern Europe

Published on February 13, 2014 at 6:02 AM · No Comments

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra™ (Infliximab) into Central and Eastern Europe. InflectraTM, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis. Alvogen and Hospira formed a strategic partnership in 2011 to provide the highest quality products and services for customers and patients throughout Central and Eastern Europe (CEE). This alliance enables us to provide increased access to the newest biosimilar drugs with state-of-the-art technology.

InflectraTM is a biosimilar medicine to the reference medicinal product, RemicadeTM (Infliximab), and is the first monoclonal antibody (mAb) to be approved through the European Medicines Agency (EMA) biosimilars regulatory pathway. RemicadeTM recorded European sales of over USD 2 billion in 2012. Alvogen will market the product in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, and Romania.

Petar Vazharov, Executive Vice President at Alvogen in the CEE region, commented: "We are delighted about the launch of InflectraTM. This product represents a major milestone for our biosimilar portfolio, which has been making great progress since its launch in partnership with Hospira in 2011. Biosimilars offer a huge opportunity for our business in Eastern Europe and with InflectraTM we demonstrate the continued growth we are achieving in this important portfolio. InflectraTM offers a more affordable - but equally effective - treatment option for sufferers of inflammatory conditions, offering compelling cost saving opportunities within the European Union."

Dr. Stan Bukofzer, Corporate Vice President and Chief Medical Officer of Hospira added: "The rigorous scientific review conducted by the European Medicines Agency and approval by the European Commission confirms that InflectraTM has demonstrated similar quality, efficacy and safety to RemicadeTM. For over a decade, biologic medicines have been pivotal in treating a range of inflammatory conditions, so the launch in Europe of InflectraTM as a biosimilar alternative represents a huge step towards the affordability of future biologic therapies."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post